In this randomized phase 3 trial involving patients with previously untreated, high-risk, early-stage, ER+/HER2− breast cancer, a significantly higher percentage of patients in the pembrolizumab‒chemotherapy arm than in the placebo‒chemotherapy arm had a pCR at the time of surgery. The gene discussed is ESR1; the disease is breast carcinoma.